SEC recommendations on Covaxin emergency use authorisation for 2-18 age group being examined: Govt

The CDSCO has also approved the Covid-19 vaccine (ZyCoV-D) of Cadila Healthcare for restricted use in an emergency situation in the age group 12 years and above

By: PTI
New Delhi | November 30, 2021 07:37 PM IST

1 min read

It is necessary to quickly initiate the process of recognition of the Corbevax vaccine and its certificate by other countries while Biological E continues to pursue WHO's EUL for it, Shringla said. (File)

The Covid Subject Expert Committee’s recommendations on granting emergency use authorisation to Bharat Biotech’s Covaxin for the 2-18 age group are being examined and additional information has been sought, Rajya Sabha was informed Tuesday.

Responding to a question on whether the government is considering Covaxin for children under 12, Union Minister of State for Health Bharati Pravin Pawar said in a written reply the interim phase 2/3 clinical trial data on healthy volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated upon in the meeting of SEC on August 26 and October 11.

This story requires a subscription

Select a plan and use IE10 code to get 10% extra off

POPULAR

EXPRESS EDGE

Daily ePaper access

Premium stories & archives

UPSC Section + UPSC Essentials Magazine

Premium stories & archives

UPSC Section + UPSC Essentials Magazine

Starts at ₹133/month

Best for UPSC aspirants

This story requires a subscription

Please Select A Plan

POPULAR

EXPRESS EDGE

Daily ePaper access

Premium stories & archives

UPSC Section + UPSC Essentials Magazine

Premium stories & archives

UPSC Section + UPSC Essentials Magazine

Starts at ₹133/month

Best for UPSC aspirants

“The committee recommended for grant of market authorization for the age group of 2 to 18 years for restricted use in an emergency situation subject to various conditions. This recommendation is being examined and additional information has been requested at the level of Central Drugs Standard Control Organisation (CDSCO),” Pawar said.

The CDSCO has also approved the Covid-19 vaccine (ZyCoV-D) of Cadila Healthcare for restricted use in an emergency situation in the age group 12 years and above, she added.